milrinone

ROUTE	ONSET	PEAK	DURATION
IV	5–15 min	unknown	3–6 hr

Monitor heart rate and BP continuously during administration. Slow or discontinue if BP drops excessively.
Monitor intake and output and daily weight. Assess patient for resolution of signs and symptoms of HF (peripheral edema, dyspnea, rales/crackles, weight gain) and improvement in hemodynamic parameters (increase in cardiac output and cardiac index, decrease in pulmonary capillary wedge pressure). Correct effects of previous aggressive diuretic therapy to allow for optimal filling pressure.
Monitor ECG continuously during infusion. Arrhythmias are common and may be life threatening. The risk of ventricular arrhythmias is increased in patients with a history of arrhythmias, electrolyte abnormalities, abnormal digoxin levels, or insertion of vascular catheters.

Lab Test Considerations:

Monitor electrolytes and renal function frequently during administration. Correct hypokalemia prior to administration to decrease the risk of arrhythmias.
- Monitor platelet count during therapy.

Toxicity and Overdose:

High Alert: Overdose manifests as hypotension. Dose should be decreased or discontinued. Supportive measures may be necessary.

Implementation ⬆ ⬇

High Alert: Accidental overdose of milrinone can cause patient harm or death. Have second practitioner independently check original order, dose calculations, and infusion pump settings.

IV Administration:

IV Push: Diluent: Loading dose may be administered undiluted. May also be diluted in 0.9% NaCl, 0.45% NaCl, or D5W for ease of administration.Concentration: 1 mg/mL.
Rate: Administer the loading dose over 10 min.
Continuous Infusion: Diluent: Milrinone drawn from vials must be diluted. Dilute 10 mg (10 mL) of milrinone in 40 mL of diluent or 20 mg (20 mL) of milrinone in 80 mL of diluent. Compatible diluents include 0.45% NaCl, 0.9% NaCl, and D5W. Premixed infusions are already diluted and ready to use. Admixed solutions are stable for 72 hr at room temperature. Stability of premixed infusions based on manufacturer's expiration date. Do not use solutions that are discolored or contain particulate matter.Concentration: 200 mcg/mL.
Rate: Based on patient's weight (see Route/Dosage section). Titrate according to hemodynamic and clinical response.
Y-Site Compatibility:
- acyclovir
- allopurinol
- amifostine
- amikacin
- aminophylline
- amiodarone
- amphotericin B liposomal
- ampicillin
- anidulafungin
- argatroban
- atracurium
- aztreonam
- bivalirudin
- bleomycin
- bumetanide
- buprenorphine
- busulfan
- butorphanol
- calcium chloride
- calcium gluconate
- carboplatin
- carmustine
- caspofungin
- cefazolin
- cefepime
- cefotaxime
- cefotetan
- cefoxitin
- ceftaroline
- ceftazidime
- ceftriaxone
- cefuroxime
- chloramphenicol
- chlorpromazine
- ciprofloxacin
- cisatracurium
- cisplatin
- clindamycin
- cyclophosphamide
- cyclosporine
- cytarabine
- dactinomycin
- daptomycin
- dexamethasone
- dexmedetomidine
- digoxin
- diltiazem
- dobutamine
- docetaxel
- dopamine
- doxorubicin hydrochloride
- doxycycline
- droperidol
- enalaprilat
- ephedrine
- epinephrine
- epirubicin
- eptifibatide
- ertapenem
- erythromycin
- etoposide
- etoposide phosphate
- fentanyl
- fluconazole
- fludarabine
- fluorouracil
- ganciclovir
- gemcitabine
- gentamicin
- glycopyrrolate
- granisetron
- haloperidol
- heparin
- hetastarch
- hydralazine
- hydrocortisone
- hydromorphone
- idarubicin
- ifosfamide
- insulin regular
- irinotecan
- isoproterenol
- ketamine
- ketorolac
- labetalol
- levofloxacin
- linezolid
- lorazepam
- magnesium sulfate
- mannitol
- melphalan
- meperidine
- meropenem
- methohexital
- methotrexate
- methylprednisolone
- metoclopramide
- metoprolol
- metronidazole
- micafungin
- midazolam
- mitoxantrone
- morphine
- mycophenolate
- nafcillin
- nalbuphine
- naloxone
- nicardipine
- nitroglycerin
- nitroprusside
- norepinephrine
- octreotide
- oxacillin
- oxaliplatin
- oxytocin
- paclitaxel
- palonosetron
- pamidronate
- pemetrexed
- pentobarbital
- phenobarbital
- phenylephrine
- piperacillin/tazobactam
- potassium acetate
- potassium chloride
- potassium phosphate
- prochlorperazine
- promethazine
- propofol
- propranolol
- remifentanil
- rocuronium
- sodium acetate
- sodium bicarbonate
- sodium phosphate
- succinylcholine
- sufentanil
- tacrolimus
- telavancin
- theophylline
- thiopental
- thiotepa
- tigecycline
- tirofiban
- tobramycin
- torsemide
- vancomycin
- vasopressin
- vecuronium
- verapamil
- vincristine
- vinorelbine
- voriconazole
- zidovudine
- zoledronic acid
Y-Site Incompatibility:
- amphotericin B deoxycholate
- amphotericin B lipid complex
- dantrolene
- diazepam
- diphenhydramine
- esmolol
- furosemide
- hydroxyzine
- imipenem/cilastatin
- lidocaine
- ondansetron
- pantoprazole
- phenytoin
- procainamide

Patient/Family Teaching ⬆ ⬇

Inform patient and family of reasons for administration. Milrinone is not a cure but is a temporary measure to control the symptoms of HF.
Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes ⬆ ⬇

Decrease in the signs and symptoms of HF.
- Improvement in hemodynamic parameters.

US Brand Names ⬆ ⬇

Code ⬆

NDC Code

0143- West-Ward Pharmaceuticals Corp
- 0143-9326- Milrinone Lactate
  - 0143-9326-10- 10 VIAL in 1 CARTON (0143-9326-10) > 20 mL in 1 VIAL (0143-9326-01)

0143- West-Ward Pharmaceuticals Corp
- 0143-9708- Milrinone Lactate
  - 0143-9708-10- 10 VIAL in 1 BOX (0143-9708-10) > 50 mL in 1 VIAL (0143-9708-01)

0143- West-Ward Pharmaceuticals Corp
- 0143-9709- Milrinone Lactate
  - 0143-9709-10- 20 mL in 1 VIAL (0143-9709-10)

0143- West-Ward Pharmaceuticals Corp
- 0143-9710- Milrinone Lactate
  - 0143-9710-25- 25 VIAL in 1 BOX (0143-9710-25) > 10 mL in 1 VIAL (0143-9710-10)

0338- Baxter Healthcare Corporation
- 0338-6010- Milrinone Lactate in Dextrose
  - 0338-6010-48- 10 BAG in 1 CARTON (0338-6010-48) > 100 mL in 1 BAG

0338- Baxter Healthcare Corporation
- 0338-6011- Milrinone Lactate in Dextrose
  - 0338-6011-37- 10 BAG in 1 CARTON (0338-6011-37) > 200 mL in 1 BAG

0409- Hospira, Inc.
- 0409-0212- MILRINONE LACTATE
  - 0409-0212-01- 10 VIAL, SINGLE-DOSE in 1 CARTON (0409-0212-01) > 10 mL in 1 VIAL, SINGLE-DOSE (0409-0212-10)

0409- Hospira, Inc.
- 0409-0212- MILRINONE LACTATE
  - 0409-0212-02- 10 VIAL, SINGLE-DOSE in 1 CARTON (0409-0212-02) > 20 mL in 1 VIAL, SINGLE-DOSE (0409-0212-11)

0409- Hospira, Inc.
- 0409-0212- MILRINONE LACTATE
  - 0409-0212-03- 1 VIAL, SINGLE-DOSE in 1 CARTON (0409-0212-03) > 50 mL in 1 VIAL, SINGLE-DOSE

0409- Hospira, Inc.
- 0409-2776- Milrinone Lactate
  - 0409-2776-02- 10 BAG in 1 CASE (0409-2776-02) > 200 mL in 1 BAG

0409- Hospira, Inc.
- 0409-2776- Milrinone Lactate
  - 0409-2776-23- 10 BAG in 1 CASE (0409-2776-23) > 100 mL in 1 BAG

63323- Fresenius Kabi USA, LLC
- 63323-617- Milrinone Lactate
  - 63323-617-10- 10 VIAL, SINGLE-DOSE in 1 TRAY (63323-617-10) > 10 mL in 1 VIAL, SINGLE-DOSE

63323- Fresenius Kabi USA, LLC
- 63323-617- Milrinone Lactate
  - 63323-617-20- 10 VIAL, SINGLE-DOSE in 1 TRAY (63323-617-20) > 20 mL in 1 VIAL, SINGLE-DOSE

63323- Fresenius Kabi USA, LLC
- 63323-617- Milrinone Lactate
  - 63323-617-50- 1 VIAL, SINGLE-DOSE in 1 CARTON (63323-617-50) > 50 mL in 1 VIAL, SINGLE-DOSE

68083- Gland Pharma Limited
- 68083-318- Milrinone Lactate
  - 68083-318-10- 10 SYRINGE in 1 CARTON (68083-318-10) > 5 mL in 1 SYRINGE (68083-318-01)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Code ⬆